Skip to content
Valspodar
Valspodar is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target ATP-dependent translocase ABCB1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938C95221——4
Myelodysplastic syndromesD009190D46——2——2
Myeloid leukemia acuteD015470C92.0——2——2
Megakaryoblastic leukemia acuteD007947C94.2——2——2
Monocytic leukemia acuteD007948——2——2
Myelomonocytic leukemia acuteD015479C92.5——2——2
Myeloid leukemiaD007951C92——2——2
Erythroblastic leukemia acuteD004915EFO_1001257C94.0——2——2
Plasma cell neoplasmsD054219——1——1
Basophilic leukemia acuteD015471C94.8——1——1
Show 1 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5022———4
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovarian neoplasmsD010051EFO_0003893C562————2
NeoplasmsD009369C802————2
LymphomaD008223C85.92————2
Kidney neoplasmsD007680EFO_0003865C642————2
Neoplasm metastasisD009362EFO_00097082————2
Renal cell carcinomaD0022921————1
SarcomaD0125091————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVALSPODAR
INNvalspodar
Description
SDZ PSC 833 is a homodetic cyclic peptide.
Classification
Protein
Drug classmultidrug resistance inhibitors: ciclosporin D derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
Identifiers
PDB—
CAS-ID121584-18-7
RxCUI228431
ChEMBL IDCHEMBL1086218
ChEBI ID8985
PubChem CID5281884
DrugBankDB11869
UNII IDQ7ZP55KF3X (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
ABCB1
ABCB1
Organism
Homo sapiens
Gene name
ABCB1
Gene synonyms
MDR1, PGY1
NCBI Gene ID
5243
Protein name
ATP-dependent translocase ABCB1
Protein synonyms
ATP-binding cassette sub-family B member 1, ATP-binding cassette, sub-family B (MDR/TAP), member 1, CD243, colchicin sensitivity, doxorubicin resistance, Multidrug resistance protein 1, P-glycoprotein 1, Phospholipid transporter ABCB1
Uniprot ID
Q14812
Mouse ortholog
Abcb1b (18669)
ATP-dependent translocase ABCB1 (P06795)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 768 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details